WHO ICTRP trial
Study on population pharmacokinetic parameters, safety, and effectiveness of…
ChiCTR2100043396 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100043396 |
|---|---|
| Public title | Study on population pharmacokinetic parameters, safety, and effectiveness of remidazolam |
| Scientific title | Remidazolam blood concentration detection and population pharmacokinetic study |
| Primary sponsor | The First Affiliated Hospital of Harbin Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Interventions | Remidazolam:Continuous infusion;Propofol :Continuous infusion |
| Registration date | Feb 13, 2021 |
| Target size | Remidazolam:210;Propofol :210 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: